ArticleBMC immunology2020

The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer.

Andrea J Luker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.